Diagnostic utility of targeted next-generation sequencing in problematic cases

American Journal of Surgical Pathology

Volumn 38, Issue 4, 2014, Pages 534-541

  Sehn, Jennifer K ^a   Hagemann, Ian S ^a   Pfeifer, John D ^a   Cottrell, Catherine E ^a   Lockwood, Christina M ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Deep sequencing; Molecular diagnostics

Indexed keywords

FIXATIVE; FORMALDEHYDE; PARAFFIN;

ARTICLE; CASE REPORT; COMPARATIVE GENOMIC HYBRIDIZATION; FEMALE; GENETICS; HUMAN; METHODOLOGY; MIDDLE AGED; NEOPLASM; TISSUE FIXATION; VERY ELDERLY;

AGED, 80 AND OVER; COMPARATIVE GENOMIC HYBRIDIZATION; FEMALE; FIXATIVES; FORMALDEHYDE; HUMANS; MIDDLE AGED; NEOPLASMS; PARAFFIN EMBEDDING; TISSUE FIXATION;

EID: 84897028806     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0000000000000161     Document Type: Article

References (40)

1. Spencer DH, Sehn JK, Abel HJ, et al. Comparison of clinical targeted next-generation sequence data from formalin-fixed and fresh-frozen tissue specimens. J Mol Diagn. 2013;15:623-633.
2. Hadd AG, Houghton J, Choudhary A, et al. Targeted, high-depth, next-generation sequencing of cancer genes in formalin-fixed, paraffin-embedded and fine-needle aspiration tumor specimens. J Mol Diagn. 2013;15:234-247.
3. Tuononen K, Mä ki-Nevala S, Sarhadi VK, et al. Comparison of targeted next-generation sequencing (NGS) and real-Time PCR in the detection of EGFR, KRAS, and BRAF mutations on formalin-fixed, paraffin-embedded tumor material of non-small cell lung carcinomasuperiority of NGS. Genes Chromosomes Cancer. 2013;52:503-511.
4. Nardi V, Sadow PM, Juric D, et al. Detection of novel actionable genetic changes in salivary duct carcinoma helps direct patient treatment. Clin Cancer Res. 2013;19:480-490.
5. Ross JS, Ali SM, Wang K, et al. Comprehensive genomic profiling of epithelial ovarian cancer by next generation sequencing-based diagnostic assay reveals new routes to targeted therapies. Gynecol Oncol. 2013;130:554-559.
6. Duncavage EJ, Abel HJ, Szankasi P, et al. Targeted next generation sequencing of clinically significant gene mutations and translocations in leukemia. Mod Pathol. 2012;25:795-804.
7. Dumur CI, Fuller CE, Blevins TL, et al. Clinical verification of the performance of the pathwork tissue of origin test: Utility and limitations. Am J Clin Pathol. 2011;136:924-933.
8. Hainsworth JD, Rubin MS, Spigel DR, et al. Molecular gene expression profiling to predict the tissue of origin and direct sitespecific therapy in patients with carcinoma of unknown primary site: A prospective trial of the Sarah Cannon research institute. J Clin Oncol. 2013;31:217-223.
9. Greco FA, Lennington WJ, Spigel DR, et al. Molecular profiling diagnosis in unknown primary cancer: Accuracy and ability to complement standard pathology. J Natl Cancer Inst. 2013;105:782-790.
10. Monzon FA, Medeiros F, Lyons-Weiler M, et al. Identification of tissue of origin in carcinoma of unknown primary with a microarray-based gene expression test. Diagn Pathol. 2010;5:3.
11. Sequist LV, Heist RS, Shaw AT, et al. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Ann Oncol. 2011;22:2616-2624.
12. Su Z, Dias-Santagata D, Duke M, et al. A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer. J Mol Diagn. 2011;13:74-84.
13. Cottrell CE, Al-Kateb H, Bredemeyer AJ, et al. Validation of a nextgeneration sequencing assay for clinical molecular oncology. J Mol Diagn. 2013. [Epub ahead of print].
14. Pritchard CC, Salipante SJ, Koehler K, et al. Validation and implementation of targeted capture and sequencing for the detection of actionable mutation, copy number variation, and gene rearrangement in clinical cancer specimens. J Mol Diagn. 2013. [Epub ahead of print].
15. Sweeney RT, Zhang B, Zhu SX, et al. Desktop transcriptome sequencing from archival tissue to identify clinically relevant translocations. Am J Surg Pathol. 2013;37:796-803.
16. Li H, Handsaker B, Wysoker A, et al. The Sequence Alignment/ Map format and SAMtools. Bioinformatics. 2009;25:2078-2079.
17. Quinlan AR, Hall IM. BEDTools: A flexible suite of utilities for comparing genomic features. Bioinformatics. 2010;26:841-842.
18. DePristo MA, Banks E, Poplin R, et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet. 2011;43:491-498.
19. Robinson JT, Thorvaldsdó ttir H, Winckler W, et al. Integrative genomics viewer. Nat Biotechnol. 2011;29:24-26.
20. Sherry ST, Ward MH, Kholodov M, et al. dbSNP: The NCBI database of genetic variation. Nucleic Acids Res. 2001;29:308-311.
21. Exome Variant Server NGESPE, Seattle, WA. Available at: Http:// evs.gs.washington.edu/EVS/. Accessed November 26, 2013.
22. Forbes SA, Bhamra G, Bamford S, et al. The Catalogue of Somatic Mutations in Cancer (COSMIC). Curr Protoc Hum Genet. 2008;57: 10.11.1-10.11.26.
23. Petitjean A, Mathe E, Kato S, et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: Lessons from recent developments in the IARC TP53 database. Hum Mutat. 2007;28:622-629.
24. Mansur MB, Hassan R, Barbosa TC, et al. Impact of complex NOTCH1 mutations on survival in paediatric T-cell leukaemia. BMC Cancer. 2012;12:9.
25. Yachida S, Jones S, Bozic I, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature. 2010;467:1114-1117.
26. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366:883-892.
27. Govindan R, Ding L, Griffith M, et al. Genomic landscape of nonsmall cell lung cancer in smokers and never-smokers. Cell. 2012;150:1121-1134.
28. Grignon DJ, Ro JY, Ayala AG, et al. Primary adenocarcinoma of the urinary bladder. A clinicopathologic analysis of 72 cases. Cancer. 1991;67:2165-2172.
29. Paner GP, McKenney JK, Barkan GA, et al. Immunohistochemical analysis in a morphologic spectrum of urachal epithelial neoplasms: Diagnostic implications and pitfalls.AmJ Surg Pathol. 2011;35:787-798.
30. Kandoth C, Schultz N, Cherniack AD, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497:67-73.
31. Okuda T, Sekizawa A, Purwosunu Y, et al. Genetics of endometrial cancers. Obstet Gynecol Int. 2010;2010:984013.
32. Rudd ML, Price JC, Fogoros S, et al. A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas. Clin Cancer Res. 2011;17:1331-1340.
33. Tennessen JA, Bigham AW, O'Connor TD, et al. Evolution and functional impact of rare coding variation from deep sequencing of human exomes. Science. 2012;337:64-69.
34. Spencer D, Vallania F, Tyagi M, et al. Performance of common methods for detecting low frequency single nucleotide variants in targeted next generation sequence data. J Mol Diagn. 2013. [Epub ahead of print].
35. Alexander RE, Lopez-Beltran A, Montironi R, et al. KRAS mutation is present in a small subset of primary urinary bladder adenocarcinomas. Histopathology. 2012;61:1036-1042.
36. Ross JS, Wang K, Al-RohilRN, et al. Advanced urothelial carcinoma: Next-generation sequencing reveals diverse genomic alterations and targets of therapy. Mod Pathol. 2013. [Epub ahead of print].
37. Ulahannan D, Kovac MB, Mulholland PJ, et al. Technical and implementation issues in using next-generation sequencing of cancers in clinical practice. Br J Cancer. 2013;109:827-835.
38. Sarhadi VK, Lahti L, Scheinin I, et al. Targeted resequencing of 9p in acute lymphoblastic leukemia yields concordant results with array CGH and reveals novel genomic alterations. Genomics. 2013;102: 182-188.
39. Han SW, Kim HP, Shin JY, et al. Targeted sequencing of cancerrelated genes in colorectal cancer using next-generation sequencing. PLoS One. 2013;8:e64271.
40. Corless CL, Barnett CM, Heinrich MC. Gastrointestinal stromal tumours: Origin and molecular oncology. Nat Rev Cancer. 2011;11: 865-878.